Tumor-derived extracellular vesicles (EVs) are under intensive study for their potential as noninvasive diagnosis biomarkers. Most EV-based cancer diagnostic assays trace supernumerary of a single cancer-associated marker or marker signatures. These types of biomarker assays are either subtype-specific or vulnerable to be masked by high background signals. In this study, we introduce using the β-sheet richness (BR) of the tumor-derived EVs as an effective way to discriminate EVs originating from malignant and nonmalignant cells, where EV contents are evaluated as a collective attribute rather than single factors. Circular dichroism, Fourier transform infrared spectroscopy, fluorescence staining assays, and a de novo workflow combining proteomics, bioinformatics, and protein folding simulations were employed to validate the collective attribute at both cellular and EV levels. Based on the BR of the tumorous EVs, we integrated immunoprecipitation and fluorescence labeling targeting the circulating tumor-derived EVs in serum and developed the process into a clinical assay, named EvIPThT. The assay can distinguish patients with and without malignant disease in a pilot cohort, with weak correlations to prognosis biomarkers, suggesting the potential for a cancer screening panel with existing prognostic biomarkers to improve overall performance.
Pancreatic cancer patients predominantly present with advanced disease at the time of diagnosis, which is the reason for its high mortality. A noninvasive fast-screening method to detect asymptomatic early-stage disease is an unmet need. Tumor-derived extracellular vesicles (EVs) bearing information from parental cells were believed to be a good candidate for noninvasive diagnosis biomarkers. Many pancreatic cancer diagnostic assays use only a single cancer-associated marker/signature, which are either subtype-specific or could be easily masked by high background signals. The purpose of this research is to develop a fast method of noninvasive diagnosis biomarkers for pancreatic cancer screening as collective attribute by analyzing the secondary structure of the EV proteins using circular dichroism (CD), Fourier transform infrared (FT-IR), and fluorescent staining. We developed a high-throughput noninvasive assay by using the β-sheet richness (BR) of the tumor-derived EVs as a target in order to recognize EVs originating from malignant and nonmalignant cells. Extracellular vesicles bearing information from parental cells, play important roles in cell−cell signaling, immune response, and metastasis. We were able to indicate that pancreatic cancer EV proteins were more β-sheet-rich than their healthy counterparts. A fast method assay was developed that combines immunoprecipitation (IP) and Thioflavin T (ThT) fluorescent dye, termed as EvIPThT, that binds directly to β-sheet-rich proteins into EVs. This assay readout of a review pilot companion showed adequate biased power contrasting samples from cancer cases, disease controls and healthy controls. This method appeared to be the simple, inexpensive, low sample, less time consuming, high-throughput, and automatable, since no β-sheet richness change was observed in the treated and nontreated cells, EvIPThT assay shows promising results as a pancreatic cancer screening assay, filling the translational gaps left by current EV detection methods. Citation Format: Komila Rasuleva, Dali Sun. Beta-sheet richness of extracellular vesicles for pancreatic cancer screening [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A039.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.